NICE now backs Jardiance for Type II diabetes

The U.K.'s NICE issued a Jardiance empagliflozin ( BI-10773) from partners Boehringer Ingelheim GmbH (Ingelheim, Germany) and Eli Lilly and Co. (NYSE:LLY) to treat Type II diabetes.

NICE concluded that revised economic analyses submitted by Boehringer showed that the oral, once-daily SGLT2 inhibitor is a "cost-effective use of NHS resources." ...